What was the primary driver of revenue growth in the third quarter of 2024?

Revenue growth in the third quarter of 2024 was primarily driven by a combination of price increases (approximately 6%), volume growth from new products (approximately 3%), volume growth from other in-line products (approximately 3%), and volume growth from key dermatology products (approximately 2%). Operational revenue growth was 14%, while reported revenue grew 11% due to a 3% unfavorable impact from foreign exchange.

How did the companion animal and livestock segments perform?

Both segments showed growth. The companion animal segment was a key driver, particularly in the U.S., fueled by products like Librela®, Solensia®, Simparica Trio®, and dermatology products. The international segment also saw growth in companion animal products, driven by dermatology, OA pain products, parasiticides, and vaccines. Livestock products also contributed positively to revenue in both U.S. and international markets.

What is the company's stance on its financial liquidity and capital resources?

Zoetis maintained a strong liquidity position with $1.71 billion in cash and cash equivalents as of September 30, 2024. The company's operating cash flows and existing financing arrangements are considered sufficient to support its cash needs. They also highlighted a $1 billion revolving credit facility available, with no amounts drawn as of the reporting date.

Are there any significant legal or tax contingencies that investors should be aware of?

The company is currently undergoing an income tax audit by the IRS for tax years 2017 and 2018, with the IRS proposing an additional tax liability of approximately $450 million, excluding interest and penalties. Zoetis disagrees with the IRS's position and intends to defend its position, but acknowledges the outcome cannot be predicted with certainty and could be material if unfavorable.

ZTS 10-Q Quarterly Report Q3 FY2024 — Revenue, Net Income, EPS

Summary

Zoetis Inc. reported strong financial results for the third quarter and the first nine months of 2024, demonstrating robust revenue growth driven by both price increases and product volume. For the three months ended September 30, 2024, total revenue increased by 11% year-over-year to $2.39 billion, with a 14% operational increase excluding foreign exchange impacts. Net income attributable to Zoetis Inc. grew by 14% to $682 million. For the nine-month period, revenue rose by 10% to $6.94 billion, and net income increased by 5% to $1.91 billion. The company's growth was propelled by its companion animal segment, particularly new products like Librela® and Solensia®, alongside strong performance in dermatology and parasiticides. While the company faces ongoing investments in R&D and SG&A, its cost management and operational efficiencies have contributed to sustained profitability. Zoetis also repurchased shares and declared dividends, indicating confidence in its financial health and commitment to returning value to shareholders.

Financial Highlights

52 data points

Beta

Revenue

$2.39B

0.7% Gross Margin

Net Income

$692.00M

0.3% Net Margin

EPS (Diluted)

$1.50

Total Assets

$14.36B

Cash & Equivalents

$1.71B

Free Cash Flow

$784.00M

Financial Statements

Beta

Revenue	$2.39B
Cost of Revenue	$701.00M
Gross Profit	$1.69B
SG&A Expenses	$565.00M
Interest Expense	$57.00M
Net Income	$692.00M
EPS (Basic)	$1.51
EPS (Diluted)	$1.50
Shares Outstanding (Basic)	452.90M
Shares Outstanding (Diluted)	453.50M

Key Highlights

1Total revenue for the third quarter of 2024 increased by 11% to $2.39 billion, with an operational increase of 14%.
2Net income attributable to Zoetis Inc. for the third quarter increased by 14% to $682 million, resulting in diluted EPS of $1.50.
3For the first nine months of 2024, revenue grew by 10% to $6.94 billion, and net income attributable to Zoetis Inc. increased by 5% to $1.91 billion.
4Companion animal products, driven by new therapies like Librela® and Solensia® for osteoarthritis pain, were significant growth drivers, particularly in the U.S. segment.
5The company maintained a strong balance sheet with $1.71 billion in cash and cash equivalents as of September 30, 2024.
6Zoetis continued its share repurchase program, authorizing a new $6 billion program in August 2024, and returned capital to shareholders through dividends.

Zoetis Inc. Quarterly Report for Q3 Ended Sep 30, 2024

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions